Abstract Number: 367 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis Patients with Non-Response to Methotrexate Monotherapy the Change in Multi-Biomarker Disease Activity Score Is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy
Background/Purpose For patients with early RA (eRA), methotrexate (MTX) is recommended as first-line treatment and in non-responders both the addition of conventional non-biological disease modifying…Abstract Number: 2587 • 2014 ACR/ARHP Annual Meeting
Predictors of Treatment Response to Tumor Necrosis Factor-Alpha Blockers in Spondyloarthritis: Systematic Review and Meta-Analysis
Predictors of Treatment Response to Tumor Necrosis Factor-Alpha Blockers in Spondyloarthritis: Systematic Review and Meta-Analysis. Background/Purpose: TNF blockers have demonstrated substantial clinical efficacy in spondyloarthritis…Abstract Number: 1741 • 2014 ACR/ARHP Annual Meeting
Anti-TNFα Treatment Increases IL-17A+ and IL-22+ T Cells in Spondyloarthritis Regardless of Concomittant Gut Inflammation
Background/Purpose The pro-inflammatory Th17 associated cytokines IL-17A and IL-22 have been proposed as important mediators of the inflammation seen in spondyloarthritis (SpA) and inflammatory bowel…Abstract Number: 576 • 2014 ACR/ARHP Annual Meeting
Dikkopf-1 (Dkk-1) Serum Levels in Axial Spondyloarthritis (axSpA) Are Related to Disease Duration
Background/Purpose: Tumor necrosis factor (TNF) alpha is responsible for induction of dkk-1 which down-regulates bone formation. Therefore, it was expected that TNF-blocker therapy would inhibit…Abstract Number: 294 • 2014 ACR/ARHP Annual Meeting
Long-Term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: To assess the pharmacokinetics (PK) and PK-efficacy correlations of body surface area (BSA)-adjusted dosing of 30 mg/m2 golimumab administered subcutaneously (SC) every 4 weeks…Abstract Number: 2558 • 2014 ACR/ARHP Annual Meeting
Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures
Background/Purpose Ankylosing spondylitis (AS) is characterized by chronic inflammation often leading to ankylosis of the spine, but also by a decrease of bone mineral density…Abstract Number: 1603 • 2014 ACR/ARHP Annual Meeting
Effect of Methotrexate on the Immunogenicity of TNF Inhibitors in Spondyloarthritis Patients
Background/Purpose: The spondyloarthritis (SpA) patients treated under TNF inhibitors (TNFi) with detectable antidrug antibodies (ADA) often develop loss of efficacy. Concomitant therapy with methotrexate (MTX)…Abstract Number: 573 • 2014 ACR/ARHP Annual Meeting
Three-Year Course and Prediction of Physical Functioning in Ankylosing Spondylitis Patients Treated with TNF-Inhibitors
Background/Purpose: Currently, only limited information is available on the long-term course of limitations in physical functioning and spinal mobility in Ankylosing Spondylitis (AS) patients receiving…Abstract Number: 272 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologics such as etanercept (ETN), approved in the UK in…Abstract Number: 2565 • 2014 ACR/ARHP Annual Meeting
The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis
Background/Purpose: Randomized clinical trials and current recommendations suggest little role for disease-modifying anti-rheumatic drugs (DMARDs) as co-therapy with anti-TNF (aTNF) agents in patients with axial-spondyloarthritis…Abstract Number: 1596 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondylarthritidies (SpA)
Background/Purpose Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of RA, PsA and AS. Our previous…Abstract Number: 572 • 2014 ACR/ARHP Annual Meeting
Objective Evaluation of Physical Functioning after TNFi Therapy in Ankylosing Spondylitis Patients; A Selection of Three Feasible Performance-Based Tests
Background/Purpose: Physical functioning is considered an important outcome domain for the evaluation of the effectiveness of therapy and the course of the disease. In an effort…Abstract Number: 248 • 2014 ACR/ARHP Annual Meeting
Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF?
Background/Purpose The present standard for measuring disease activity in AS is the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) which focuses on five major symptoms…Abstract Number: 2521 • 2014 ACR/ARHP Annual Meeting
Analysis on Predictors for Long-Term Clinical Efficacies of Golimumab in Patients with Rheumatoid Arthritis
Background/Purpose The GO-FORTH, phase 2/3 clinical trial was conducted to examine the efficacy and safety of Golimumab (GLM) plus MTX in Japanese patients (pts) with…Abstract Number: 1553 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Background/Purpose: Early non-response to biologic therapy has been shown to be associated with a low probability of long-term response in rheumatoid arthritis1 and psoriasis2. However,…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 29
- Next Page »